Inscripta, a US-based genome engineering technology producer backed by medical technology holding group Institut Mérieux, has raised $150m for the close of its series E round.
The round was co-led by investment and financial services group Fidelity and funds and accounts advised by T Rowe Price, with participation from investment bank Morgan Stanley’s Counterpoint Global subsidiary, D1 Capital Partners, Durable Capital Partners, Foresite Capital and JS Capital.
Inscripta has built an automated gene-editing system that enables users to generate million of edited cells for life science-based testing and research.
Paladin Capital Group led a $125m series D round for Inscripta in December 2019, that included JS Capital, Oak HC/FT and unspecified existing backers.
The company closed a $106m series C round in April 2019 that was backed by Institut Mérieux’s investment vehicle, Mérieux Développement, as well as Paladin Capital, Venrock, Foresite, MLS Capital and NanoDimension.
Inscripta had previously raised $29m of funding across its 2016 series A round and 2017 series B rounds, from investors including NanoDimension, Venrock, Foresite, Paladin Capital and MLS Capital.